Diligence memo · auto-generated · as of July 2, 2026
Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Venatorx Pharmaceuticals, Inc. operates in Pharmaceuticals, based in MALVERN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Venatorx Pharmaceuticals, Inc. has raised $124M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $35M on 2023-02-17.
Most recent recorded round closed around 2023-02-17.
Valuation (modeled)modeled
Provath models Venatorx Pharmaceuticals, Inc. at approximately $421M (range $74M–$979M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.24× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 3.4 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 2.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 93% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 79% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Cxl Ophthalmics, Inc., Delex Healthcare Group, Inc..
Peoplefiled
17 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.